Akebia Therapeutics (AKBA) Common Equity (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Common Equity of $27.4 million for Q1 2026, up 11.37% year-over-year from $24.6 million in Q1 2025, and down 16.05% quarter-over-quarter from $32.6 million in Q4 2025.
Akebia Therapeutics (AKBA) Common Equity (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Common Equity for 14 consecutive years, with $27.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 11.37% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $27.4 million (up 11.37% YoY), while the FY2025 annual figure was $32.6 million, up 166.3% from the prior year.
- Common Equity slipped to $27.4 million in Q1 2026 per AKBA's latest filing, from $32.6 million in the prior quarter.
- Across five years, Common Equity topped out at $58.9 million in Q2 2022 and bottomed at -$50.4 million in Q3 2024.
- Historically, Common Equity has averaged -$1.5 million across 5 years, with a median of $5.2 million in 2022.
- Annual changes were most pronounced in 2023 — Common Equity tumbled 684.78% — and 2025, when it jumped 190.18%.
- Akebia Therapeutics' Common Equity stood at $5.2 million in 2022, then sank by 684.78% to -$30.6 million in 2023, then plunged by 60.82% to -$49.2 million in 2024, then surged by 166.3% to $32.6 million in 2025, then retreated by 16.05% to $27.4 million in 2026.
- Business Quant data shows AKBA's Common Equity at $27.4 million in Q1 2026, $32.6 million in Q4 2025, and $41.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 25.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.02 Mn |
| Mar 31, 2026 | 27.38 Mn |
| Dec 31, 2025 | 32.61 Mn |
| Sep 30, 2025 | 41.59 Mn |
| Jun 30, 2025 | 29.22 Mn |
| Mar 31, 2025 | 24.58 Mn |
| Dec 31, 2024 | -49.19 Mn |
| Sep 30, 2024 | -50.40 Mn |
| Jun 30, 2024 | -33.75 Mn |
| Mar 31, 2024 | -27.26 Mn |
| Dec 31, 2023 | -30.58 Mn |
| Sep 30, 2023 | -39.42 Mn |
| Jun 30, 2023 | -26.81 Mn |
| Mar 31, 2023 | -19.12 Mn |
| Dec 31, 2022 | 5.23 Mn |
| Sep 30, 2022 | 8.26 Mn |
| Jun 30, 2022 | 58.94 Mn |
| Mar 31, 2022 | 22.58 Mn |
| Dec 31, 2021 | 74.01 Mn |
| Sep 30, 2021 | 137.15 Mn |